RxDoctor Payments Data

Kristopher Patnugot, DO

Family Medicine · Royal Oak, MINPI 1649614470

Payments from drug & device makers

$5,774in general payments, 2019–2025

Across 332 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Orexo US, Inc.$1K
  • Indivior Inc.$486
  • Otsuka America Pharmaceutical, Inc.$363
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
  • Lundbeck LLC$347
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$5,753100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,774 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$10,650
Medicare patients
30
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl348$46,168
SuboxoneBuprenorphine Hcl/Naloxone Hcl67$30,721
ZubsolvBuprenorphine Hcl/Naloxone Hcl15$8,541
TrintellixVortioxetine Hydrobromide15$8,162
Sumatriptan Succinate14$1,376
Atorvastatin Calcium51$585
Gabapentin68$508
Ibuprofen15$423
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$368
Levothyroxine Sodium26$332
Methocarbamol13$306
Lisinopril23$278
Pregabalin20$247
Losartan Potassium29$209
Tamsulosin Hcl11$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone$21$46,168348 claims
Indivior Inc.Suboxone$486$30,72167 claims
Orexo US, Inc.Zubsolv$1,029$8,54115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$86$8,16215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →